Research Studies: Corticobasal Degeneration & Progressive Supranuclear Palsy
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL, Enrolling)
This research study is looking to learn more about cognition and/or movement problems in patients with frontotemporal dementia
Patients who qualify are those who have been diagnosed with the following or have a blood relative who is diagnosed with the following:
- Sematic variant Primary Progressive Aphasia (PPA)
- Progressive Supranuclear Palsy (PSP)
- Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD-ALS)
Participation includes an evaluation of cognition, a physical examination, questionnaires, and a sample of blood. Patients may also be asked for an MRI scan or cerebrospinal fluid. If FTLD runs in the patient's family, they may be asked to return in one year for a follow-up appointment where assessments will be repeated. For more research study please contact our research coordinator Kim Thomas Tel: 858-822-5751 or via email firstname.lastname@example.org.
- Corticobasal Degeneration
Four Repeat Tauopathy Neuroimaging Initiative (4RTNI-2) (active)
This study is evaluating the best method of analysis to track patients with Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) over time. During this 2 year-long study, patients will be asked to come in for 3 study visits (at baseline, 6 month, 12 months, and 24 months) to complete a neurological examination, study partner questionnaires, memory testing, lumbar puncture, biospecimen collection, MRI, and a PET scan. Patients with PSP or CBD between the ages of 45 - 90 with a reliable study partner are eligible. For more information on this study, please contact Veronica Lopez at 858-822-5786 or email@example.com.
- Progressive Supranuclear Palsy (PSP)
Assessing Falls in Parkinson's Disease and other Movement Disorders
This research study is looking to validate a wearable
multi-modal system in patients with an increased risk of falling. This
technology could allow physicians to monitor and understand what causes certain
patients to fall. Participation will consist of one study visit and two at home
sessions with the multi-modal monitoring system. Patients with movement
disorders may qualify for this study if they are over 50 years of age and have
a history of falls. Enrollment on hold.
Epidermal Electronic System (EES) Sticker Sensory Studies
Dr. Litvan is studying the applicable uses of a sticker sensor called epidermal electronic system (EES) sensor. There are three uses currently being studied:
This sub-study is studying if this sticker sensor can be used to find out more about processing in the brain. The sticker sensor will be placed on the forehead and be connected to a portable EEG to measure their brain waves while viewing visual stimulus on a computer screen and/or listening to auditory stimulus. Patients may be asked to take this system home and complete 15 minutes of testing a day for a week. Currently enrolling.
Prior studies have demonstrated a hyper-activation of a laryngeal muscle at rest in patients with PSP with needle-based EMG. This sub-study is studying if this EES sticker sensor and standard transcutaneous EMG electrodes can replicate this study in a non-invasive manner. During this study, the sticker sensor will be placed on the throat to record muscle activation while the subject is making different phonations. Currently enrolling.
For more information on this study, please contact (858) 822-MOVE or email firstname.lastname@example.org.
Familial PSP Study
This research study is hoping to identify gene variation involved
in PSP. Patients diagnosed with PSP and who have a living blood relative with a
neurological or psychological disorder may be eligible for this study. For more information on this study, please contact (858) 822-MOVE or email email@example.com.
Phase I Multiple Dose BMS Antibody Treatment
In collaboration with Bristol-Myers Squibb, Dr. Litvan is recruiting for a clinical trial to evaluate whether multiple doses of an investigational drug called BMS-986168 given intravenously over a course of about 6 months is safe and well-tolerated in subjects with PSP. BMS-986168 is an immunotherapy (antibody) drug designed to bind to and remove the free eTau (extracellular tau), which is believed to build up to abnormally high levels in the brains of subjects with PSP. Patients with PSP between 50 - 85 years of age who are able to walk with minimal assistance, willing to undergo 3 lumbar punctures (LPs) and 3 MRI scans, and have an available study partner may be eligible for this study. This study has open label extension continuation (not placebo-controlled) study available for patients after completion of the initial study. For more information on this study, please contact Cindy Lawrence at 858-246-2537 or firstname.lastname@example.org.
Enrollment on hold
Postural Stability in PSP
Drs. Litvan and medical Student Danielle Gillard are studying postural stability in patients with PSP using an iPAD application. Eligible patients should be between 40-90 years of age, able to stand comfortably for 5 minutes unaided, and have no memory problems. For more information, please call (858) 822-MOVE or email email@example.com. Estimated start date May 2016.